Net income fell 11.2% to $1.73 billion, though the decline was due principally to restructuring and charges, while group sales increased 2.0% to $9.81 billion. Proprietary pharmaceutical revenues climbed 4.9% to $4.38 billion.
Abbott announced yesterday that they have received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System to treat coronary artery disease. With the introduction of XIENCE PRIME in the U.S., Abbott, the worldwide leader in drug eluting stent technology, offers an expanded range of drug eluting stents
Abbott Laboratories yesterday announced that they will split off their $18 billion drugs division into a new, as-yet unnamed company, as Abbott start to reverse their diversification of recent years. The pharmaceutical unit will be named later in the year, while the remainder – diagnostics, devices, nutrition and branded generics – will keep the Abbott
Biogen Idec and Abbott Laboratories have reported promising results in a Phase IIb trial of daclizumab, their once-monthly injectable treatment for multiple sclerosis. Top-line results from the dose-ranging SELECT trial in patients with the relapsing-remitting form of MS indicate that treatment with daclizumab at a dose of 150mg given by subcutaneous injection once every four
